Why bother doing fancy tests in patients with CLL?

Slides:



Advertisements
Similar presentations
Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.
Advertisements

Current Treatment Options in MDS Dick Wells MD, DPhil, FRCPC Director, Crashley Myelodysplastic Syndrome Research Laboratory Odette Cancer Centre.
Compliments of Bayer HealthCare Pharmaceuticals Inc.
Therapy of enzyme defects: general considerations ● How many organs are affected by the enzyme defect: One organ, a few, or all organs? ● How severe is.
Staff Oncologist, Mayo Clinic Arizona
CLL- Chronic Lymphocytic Leukemia
Also known as lymphoplasmacytic lymphoma A rare type of non-Hodgkin lymphoma WM affects lymphoplasmacytic (LPL) Cells B-Cells LPL Cells Plasma Cells Abs.
West Midlands Regional Genetics Laboratory
Leukemia By Mary Chen and Genesis Pimentel
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
LEUKEMIA. What Is It? Leukemia is a type of cancer that starts in the tissue that forms blood.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
 “Resident Expert Presentation” Leukemia Khadija Andrews CEP 661 Medical Psychology.
By:Ashley Druck.  Is cancer that starts in the blood, forming tissues such as the bone marrow and causes large numbers of blood cells to be produced.
Phase I Trial of Autologous CD19-Targeted CAR-Modified T Cells as Consolidation After Purine Analog-Based First-Line Therapy in Patients with Previously.
Chronic lymphocytic leukemia Prognosis and treatment Emili Montserrat Institute of Hematology and Oncology. University of Barcelona ESH - Hammamet, 28.
What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.
Chronic lymphocytic leukemia What is C.L.L. ? a chronic disease one particular type of lymphocyte (B-cells) accumulates. not rapidly growing and proliferating.
Chronic myeloid leukaemia Cancer of granulocyte production Too many (non functioning) granulocytes are produced Bone marrow is overcrowded with ineffective.
Taylor Edwards. What is Leukemia? Leukemia is a type of blood cancer that begins in the bone marrow. The bone marrow starts making abnormal white blood.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Paige Myers & Mahek Shah.  Cancer is a disease in which the DNA of cells becomes damaged or changed and the affected cells do not respond to apoptosis.
Leukemia By: Manuel Gomez. What is leukemia  Leukemia also called blood cancer  A disease in which the bone marrow and organs that form blood, produce.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
New research areas in personalised medicines
100,000 genomes project and haematological malignancy
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
Leukemia An estimate reveals over 327,520 people in the U.S. are living with Leukemia. In India leukemia is ranked among the list of top cancers affecting.
Geisler C et al. Proc ASH 2011;Abstract 290.
The chronic lymphoid leukaemias
Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12
Idelalisib plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a.
Enzyme and gene therapy of enzyme defects
Public observer slides
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Chronic lymphocytic leukemia (CLL)
Therapy of enzyme defects: general considerations
Goede V et al. Proc ASH 2014;Abstract 3327.
CHRONIC MYELOID LEUKEMIA (CML)
MRD in Myeloma: the Future is Here
Stephen Ansell, MD, PhD Mayo Clinic
Current and Future Goals in the Treatment of Relapsed CLL
Goals of Therapy in Relapsed CLL
Novel and Emerging Approaches to Treating CLL
Management Challenges in CLL
Updates in Lymphoma From Recent Congresses
Leukemia.
Navigating New Oral Treatment Algorithms in CLL
Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL
Personalized Therapy in Relapsed or Refractory CLL
Leukemia An estimate reveals over 327,520 people in the U.S. are living with Leukemia. In India leukemia is ranked among the list of top cancers affecting.
What is the best frontline regimen for CLL patients
Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.
Non-Chemotherapy Combinations in CLL
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Personalised Medicine – Case Study Herceptin®
Assessing New Paradigms in CLL: MRD Negativity
Enzyme and gene therapy of enzyme defects
Dr Parag Jasani Consultant Haematologist UCLH
First-Line FCR: Effect of del(17p) on PFS and OS
CLL - When to treat, how to treat
Tailoring Therapy in the Newly Diagnosed Patient With CLL
Leukemia By: Fabiola Dominguez.
Lymphoma in Pediatrics 23rd Nov 2018
MRD Analysis in Chronic Lymphocytic Leukemia
Treatment guidelines - Chronic Lymphocytic Leukaemia All patients should be considered for available clinical trials 17p- status should be checked prior.
Join us today and together we will fight CLL
Overall Survival and Progression-free Survival
Treatment Initiation and Selection in Newly Diagnosed CLL
Presentation transcript:

Why bother doing fancy tests in patients with CLL? Andrew R Pettitt University of Liverpool

Some basic facts about CLL Annual incidence about 5 per 100,000 per year Male:Female ratio about 2:1 Less common in individuals from the Far East Predominantly a disease of older people (7th decade)

Blood picture in CLL

Diagnosis of CLL CD19 PE Con PE CD2 PE CD22 PE CD79b PE CD19 Lambda PE Con FITC CD5 FITC FMC7 FITC CD23 FITC CD20 FITC Kappa FITC

Accumulation of CLL cells in bone marrow Low red cells and platelets

Accumulation of CLL cells in liver and spleen Low red cells and platelets

Accumulation of CLL cells in lymph nodes Immune deficiency Abnormal immune reactions Haemolytic anaemia ITP

Symptoms of CLL

Complications of CLL

CLL variability The clinical course of CLL varies between patients Basic clinical features can predict survival How much the disease has already grown by the time it is diagnosed (stage) How fast it carries on growing after diagnosis (lymphocyte doubling time)

Tumour burden and prognosis

Lymphocyte doubling time and prognosis Mollica S et al. Cancer 2001;92:713-9

Why do we need fancy tests? Tumour burden at diagnosis predicts survival but not much else Patients with low tumour burden want to know their prognosis without having to wait to see how quickly their disease grows Doctors want information that helps with specific clinical decisions

Prognostic tests in newly diagnosed patients with low tumour burden “Big picture” from patient’s perspective Chromosome abnormalities “CLL FISH panel” for 17p-, 11q-, +12 and 13q- Cell of origin IGHV mutational status

Chromosome abnormalities Fluorescence in-situ hybridisation (FISH) Dohner H et al. NEJM 2000; 343:1910-1916

Cell of origin (IGHV “mutated” or “unmutated”)

Why do we need fancy tests? Tumour burden at diagnosis predicts survival but not much else Patients with low tumour burden want to know their prognosis without having to wait to see how quickly their disease grows Doctors want information that helps with specific clinical decisions

Clinical decisions that doctors need help with When to start treatment? What treatment to give? What to do once treatment has finished?

Bendamustine ± rituximab What treatment to give? More effective Better tolerated Bendamustine ± rituximab Chlorambucil ± CD20 Mab FCR DNA-damaging chemotherapy

But… not all patients respond to chemotherapy FCR arm of German CLL8 trial Progression-free survival 17p deletion Hallek M et al. Lancet 2010;376:1164-74

CLL cell with 17p deletion What’s going on at 17p? CLL cell with 17p deletion Normal cell TP53 gene on chromosome 17p TP53 mutation p53 mRNA Non-functional mutant p53 protein p53 protein Wild-type p53 protein

TP53 mutation can occur in the absence of 17p- and vice versa; both have the same effect 17p deletion TP53 mutation

What does wild-type p53 do that’s so important? ‡ What does wild-type p53 do that’s so important? p53 activation Chemotherapy Kills CLL cells Stops CLL cells from growing Stops CLL cells from turning even nastier Non-chemo drugs Steroids* Campath* Lenalidomide* Ofatumumab Ibrutinib Idelalisib Venetoclax *Not approved in CLL

How do ibrutinib and idelalisib work?

How does venetoclax work?

What does NICE say? Idelalisib in CLL (TA359; October 2015). Approved for First-line treatment of patients with a 17p deletion or TP53 mutation Previously treated CLL relapsing within 2 years of last therapy Ibrutinib in CLL (TA429; Jan 2017). Approved for Previously treated CLL Venetoclax in CLL (STA944). Rejected Feb 2017 Further committee meeting March 2017 Final outcome June 2017 Licenced for patients who have failed a BCR inhibitor and either have a 17p deletion or TP53 mutation, or have relapsed after chemotherapy.

Standard chemo-based approach Take-home message #1 Treatment indicated FISH No 17p- or TP53 mutation 17p- or TP53 mutation Standard chemo-based approach Non-chemo drugs

Clinical decisions that doctors need help with When to start treatment? What treatment to give? What to do once treatment has finished?

When to start treatment? Trials have shown no benefit in treating patients with asymptomatic early stage disease But… blanket approach with old-fashioned drugs Ongoing studies with newer drugs targeting patients at high risk of early progression IGHV, FISH and TP53 mutation may be useful outside of trials To identify those patients who can be safely followed up infrequently and/or “remotely” To identify those patients who might benefit from starting treatment sooner rather than later: High risk of Richter transformation Likely to grow quickly

Take-home message #2 FISH IGHV New diagnosis of CLL Low-risk No 17p-/11q- No TP53 mutation IGHV mutated, no VH3-21, VH4-39 or stereotype 17p-/11q- TP53 mutated IGHV unmutated, VH3-21 VH4-39 or stereotype Low-risk Infrequent/ remote follow-up High-risk Low threshold for starting treatment

Clinical decisions that doctors need help with When to start treatment? What treatment to give? What to do once treatment has finished?

What to do when treatment has finished? If long remission predicted Infrequent or remote follow-up If high risk of early relapse Potential role for maintenance therapy If high risk of Richter transformation Potential role for allogeneic transplantation

Tests that can predict what happens after treatment has finished Pre-treatment IGHV status IGHV unmutated = faster growing = earlier relapse IGHV4-39 or stereotyped BCR = high risk of Richter transformation Pre-treatment FISH 11q- = faster growing 17p- = faster growing and higher risk of Richter transformation Pre-treatment TP53 mutation status TP53 mutation = faster growing and higher risk of Richter transformation Post-treatment minimal residual disease (MRD) Can detect 1 CLL cells among 10,000 normal white blood cells Deeper remissions = longer remissions

Infrequent/ remote follow-up Take-home message #3 Treatment completed Bone marrow for MRD MRD -ve MRD +ve Infrequent/ remote follow-up Close follow-up Maintenance?

Summary of how tests can help with decision making Result Decisions at diagnosis Treatment decisions Post treatment decisions IGHV analysis Mutated Infrequent/ remote follow-up Limited Unmutated or VH3-21 Close follow-up Maintenance? VH3-49 or stereotyped Early treatment Allograft? FISH 17p- Non-chemo drugs 11q- TP53 mutation TP53 mutated Post-treatment MRD Negative N/A Positive

Mutations in CLL – much still to learn TP53, ATM, NOTCH1, SF3B1, BIRC3, LRP1B, SAMHD1, FBXW7, PCLO, HIST1H1E, XPO1, CHD2, MYD88, POT1 and ZFPM2 Detectable with “next generation sequencing” TP53 mutation Other mutations ATM mutation Sozan Karim, PhD student

Summary of key tests available in 2017 and when they should be performed At diagnosis Pre-treatment Post-treatment IGHV status Yes Not if already done No FISH Yes (can change) TP53 mutation MRD N/A

Do currently available tests give all the answers? Our understanding of why CLL behaves differently in different patients is very incomplete Ongoing work to improve this understanding, e.g. Genomics England Ltd allocated £3.5M to sequence the entire genetic code of up to 1000 samples stored in the UK CLL Trials Biobank in Liverpool (ARCTIC, AdMIRe, RIAltO, CLL210, CLEAR) Analysis of all the proteins expressed by CLL cells to understand how alterations in the genetic code affect the expression of proteins and how this influences therapy response and disease behaviour Clinical trials, sample collection and laboratory research are essential Teamwork is paramount